DV
Dividend Vision

LEGN — Legend Biotech Corporation

Legend Biotech Corporation (LEGN)

Total return is -44.9% over the past 6.2 years, 210.1 points behind SPY at 165.2%. Its deepest 1-year drawdown was 55.8%.

Legend Biotech Corporation is a healthcare equity stock that focuses on biopharmaceutical development and commercialization. As an individual stock rather than a diversified fund, it does not provide regular dividend distributions or carry a traditional expense ratio. The holding appeals primarily to growth-oriented investors seeking exposure to the biotech sector, rather than to income-focused dividend investors.

LEGN key facts

Asset type
Stock
Asset class
Equity
Inception date
06/05/2020
Distribution frequency
None
Last close
$20.37
Market cap
$3,947,084,032
Average volume
2017300.0
Beta
0.387
Payout ratio
0.0
Forward P/E
136.9863
EPS
$-0.50